Heather Bresch, the CEO of Mylan, which manufactures the EpiPen, said she hopes the pricing controversy over the lifesaving device for allergy sufferers should lead to changes in how drugs are priced in the U.S.
She made her comments at the Forbes Healthcare Summit in New York Thursday.
In her 25 years at Mylan, including many years as a lobbyist in Washington before she became CEO, Bresch said pricing has changed little. Policymakers need to lift the veil on how drugs are priced so the consumer knows what the prescription really costs. From there, changes can be made, Bresch said.
